



- UCI 09-17** Biology of Human Melanocytes and Keratinocytes (Meyskens)
- UCI 14-25** Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)
- UCI 14-36** A Correlative Study to Examine Cancer Molecular Alterations Using a Blood Based Assay (Seery)
- UCI 16-01** (PAINT)-Pathway Analyses for Individualized Network Therapeutics for Cancer (Nelson)

## Epidemiologic/Correlative

## Prevention

- UCI 14-92** Phase IV Study of Daylight Photodynamic Therapy with Aminolevulinic Acid for Actinic Keratoses (Zachary)

# Skin CA & Melanoma

## Therapeutic

- UCI 16-96** Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid (Ou)

- UCI 16-45-SUSPENDED-** A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K  $\delta/\gamma$  inhibitor, in Patients with Relapsed or Refractory T-cell Lymphoma (Pinter-Brown)

- UCI 16-46** A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Injection in Patients with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-Type (Pinter-Brown)

- ECOG-EAY131** Molecular Analysis for Therapy Choice (MATCH) (Seery)

- UCI 16-92** A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib versus Placebo plus Cobimetinib and Vemurafenib in Previously Untreated BRAF V600 Mutation-Positive Patients with Metastatic or Unresectable Locally Advanced Melanoma (Fruehauf)

- SWOG S1404** A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma (Yamamoto)

- UCI 17-09\*\*** A Randomized, Double-Blind, Placebo-Controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma (Fruehauf)

- SWOG S1609** (CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

- UCI 17-50\*\*** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

- UCI 17-58\*\*** Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas (Pinter-Brown)

## Screening/Diagnostic

- UCI 11-30** Skin imaging with Technologies in Development (Kelly)
- UCI 14-05** Multi-Center Evaluation of Oncogenesis via Spectral Analysis with the Melanoma Advanced Imaging Dermoscope (mAID) (Linden/Kelly)
- UCI 13-13** Pilot study on in-vivo non-invasive skin imaging using multiphoton microscopy and multispectral imaging (Kelly)
- UCI 15-08** Spectral comparison between Spatially Modulated Quantitative Spectroscopy (SMoQS) and Polarization Sensitive Hyperspectral Multimode Dermoscopy for the purpose of skin compositional analysis (Kelly)
- UCI 16-82** DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study #4
- UCI 16-37\*\*** Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome (Pinter-Brown)